drugset
drugset / Trial / NCT02082262

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

NCT02082262 ↗

Phase 3 Completed 140 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.

Timeline

Start
2014-03
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AGN-229666 Unknown — Other

Indications

conjunctivitis